Butamirate


Generic Medicine Info
Indications and Dosage
Oral
Non-productive cough
Adult: As 50 mg tab: 2 or 3 tabs daily at intervals of 8 or 12 hours. As 7.5 mg/5 mL syr: 22.5 mg (15 mL) up to 4 times daily. Max: 90 mg (60 mL) daily. Dosage recommendations may vary among countries or individual products (refer to specific product guidelines).
Child: Dosage recommendations may vary among countries or individual products (refer to specific product guidelines).
Special Precautions
Hepatic and renal impairment. Pregnancy and lactation.
Adverse Reactions
Gastrointestinal disorders: Nausea, diarrhoea.
Immune system disorders: Hypersensitivity reaction.
Nervous system disorders: Drowsiness, dizziness.
Skin and subcutaneous tissue disorders: Rash, urticaria.
Patient Counseling Information
This drug may cause drowsiness or dizziness, if affected, do not drive or operate machinery.
Overdosage
Symptoms: Nausea, vomiting, diarrhoea, somnolence, dizziness, hypotension. Management: Supportive treatment.
Drug Interactions
Concomitant use with other cough medicines may cause an accumulation of bronchial secretions in the lungs.
Action
Description:
Mechanism of Action: Butamirate is an antitussive structurally unrelated to opioids. To suppress cough, it acts centrally by decreasing the tussigenic reflex. It also has peripheral anti-inflammatory and bronchospasmolytic activity.
Pharmacokinetics:
Absorption: Rapidly and completely absorbed. Time to peak plasma concentration: 1.5 hours (syr).
Distribution: Plasma protein binding: Approx 95%.
Metabolism: Metabolised via hydrolysis into 2-phenyl butyric acid and diethylaminoethoxyethanol.
Excretion: Via urine (as metabolites). Elimination half-life: 6 hours.
Chemical Structure

Chemical Structure Image
Butamirate

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 28892, Butamirate. https://pubchem.ncbi.nlm.nih.gov/compound/28892. Accessed July 27, 2022.

Storage
Store below 30°C.
MIMS Class
Cough & Cold Preparations
ATC Classification
R05DB13 - butamirate ; Belongs to the class of other cough suppressants.
References
Anon. Butamirate. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 08/06/2022.

Buckingham R (ed). Butamirate Citrate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/06/2022.

Confomed 7.5 mg/5 mL Syrup, 50 mg Sustained Release Tablet (Lloyd Laboratories, Inc). MIMS Philippines. http://www.mims.com/philippines. Accessed 08/06/2022.

Sinecod Forte 7.5 mg/5 mL Syrup, 50 mg Sustained-release Tablet (Interphil Laboratories, Inc.). MIMS Philippines. http://www.mims.com/philippines. Accessed 08/06/2022.

Disclaimer: This information is independently developed by MIMS based on Butamirate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in